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The influence of diabetes on regulatory mechanisms and specific receptors implicated in the response of isolated rabbit renal artery to
endothelin-1 was examined. Endothelin-1 induced a concentration-dependent contraction that was less potent in arteries from diabetic rabbits than
in arteries from control rabbits. Endothelium removal or N G-nitro-L-arginine (L-NOARG) enhanced contractions to endothelin-1 either in control
and diabetic arteries. Indomethacin inhibited endothelin-1-induced response in control arteries, but enhanced it in diabetic arteries. In contrast to
that observed in rubbed and in L-NOARG treated arteries, in the presence of indomethacin the contractile action of endothelin-1 was higher in
diabetic arteries than in control arteries. Nimesulide enhanced endothelin-1 contractions both in control and diabetic arteries. Cyclo-(D-Asp-Pro-D-
Val-Leu-D-Trp) (BQ-123, endothelin ETA receptor antagonist), attenuated endothelin-1 vasoconstriction in control rabbits, while vasoconstriction
resulted increased in diabetic rabbits. 2,6-Dimethylpiperidinecarbonyl-γ-Methyl-Leu-Nin-(Methoxycarbonyl)-D-Trp-D-Nle (BQ-788, endothelin
ETB receptor antagonist), enhanced the contractile response in control rabbit arteries without modifying this response in diabetic rabbits. In
summary, diabetes decreases the sensitivity of the rabbit renal artery to endothelin-1 by decreasing the ratio between vasoconstrictor and
vasodilator prostanoids released after activation of endothelin ETA receptors.
© 2006 Elsevier B.V. All rights reserved.Keywords: Diabetes; Arachidonic acid derivatives; Cyclooxygenase; Endothelin-1; Endothelin ETA and ETB receptors; Endothelium; NO (nitric oxide); Renal artery1. Introduction
The WHO Multinational Study of Vascular Disease in
Diabetes reported that cardiovascular disease is the most
common cause of death accounting for 44% of deaths in Type
I diabetes mellitus, followed by renal disease accounting for
21% of deaths (Morrish et al., 2001).
Vascular reactivity is regulated by a complex interaction
between vasoconstrictor and vasodilator substances released
from endothelium, smooth muscle cells, perivascular nerve
endings and blood cells. The endothelium has a decisive role in
regulating both the tone and the growth of the vessel wall by
maintaining a critical balance between different constrictor⁎ Corresponding author. Tel.: +34 963544903; fax: +34 963543395.
E-mail address: francisco.j.miranda@uv.es (F.J. Miranda).
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doi:10.1016/j.ejphar.2006.01.043(endothelin-1, angiotensin II, thromboxane A2, prostaglandin
H2) and relaxant (nitric oxide, prostacyclin, endothelium-
derived hyperpolarizing factor) substances. Accordingly, the
vasoconstrictor and mitogenic actions of endothelin-1 are
opposed to those of vasodilator and antigrowth factors such
as nitric oxide (NO) and prostacyclin secreted by endothelial
cells. Smooth muscle cells are able to release vasoconstrictor
and vasodilator prostaglandins. ATP, noradrenaline and neuro-
peptide Y are co-stored and released from vascular neuroeffec-
tor junctions (Huidobro-Toro and Donoso, 2005) and nitrergic
perivascular nerve endings have been histochemically and
functionally identified in the vessel wall (Haberberger et al.,
1997; Jurzik et al., 2005).
Prostanoids derived from endogenous cyclooxygenases
(COX)-mediated arachidonic acid metabolism play important
roles in the maintenance of renal blood flow and salt and water
Table 1
Body weight and glycaemia in control and diabetic rabbits
Body weight (kg) Glycaemia (mmol/l) n
Control rabbits
Initial time 2.50±0.08 5.9±0.2 25
6 weeks after 3.50±0.07 5.8±0.2 25
Diabetic rabbits
Initial time 2.52±0.08 5.9±0.2 23
6 weeks after 3.08±0.08 a 20.3±0.6 a 23
Results are means±S.E.M.
a Significantly different from corresponding value in control rabbits, P<0.01.
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two major products of COX are thromboxane A2, which is
mainly formed by the constitutive isoform of COX, COX-1, and
prostacyclin which is mainly produced in vascular cells by
COX-1 and the inducible isoform COX-2. COX-1 is expressed
constitutively in vascular endothelial cells and in smooth
muscle cells whereas COX-2 may be induced in these tissues in
response to vascular injury (Habib et al., 1993; Rimarachin et
al., 1994).
Diabetes alters the responsiveness of different vascular beds
to several vasoconstrictors and vasodilators, and it has been
hypothesised that endothelial dysfunction could partially
explain many of these altered responses (Haller, 1997; De
Vriese et al., 2000). Since the discovery of endothelin-1 as the
most potent vasoconstrictor and pressor substance (Yanagisawa
et al., 1998), several events have suggested its implication in
various cardiovascular disorders, including those related to
diabetes mellitus. It is clear that many of the well-known
metabolic abnormalities encountered in diabetes mellitus, such
as those affecting plasma insulin, glucose and lipid levels,
contribute individually and synergistically to alterations in the
release and action of endothelin-1 (Hopfner and Gopalakrish-
nan, 1999). Endothelin-1 exerts a powerful vascular influence
on the renal circulation, resulting in decreases in renal blood
flow and glomerular filtration (Oyekan and McGiff, 1998).
Urinary excretion of endothelin-1 is decreased in patients with
recent-onset diabetes mellitus, thus suggesting a possible role of
endothelin-1 in the pathogenesis of early diabetic nephropathy
(Lam et al., 1995). Excessive endothelin-1 action in the diabetic
glomerulus can cause enhanced matrix accumulation, protein-
uria, and reduced glomerular filtration rate, existing abundant
evidence in vivo that endothelin-1 antagonists ameliorate
glomerular injury in animal models of diabetic nephropathy
(Sorokin and Kohan, 2003).
We have previously reported that diabetes changes endothe-
lial modulatory mechanisms in the rabbit renal artery (Alabadí
et al., 2001; Miranda et al., 2002). In two recent studies we have
reported that diabetes induces hyperreactivity of the rabbit
basilar (Alabadí et al., 2004) and carotid (Lloréns et al., 2004)
arteries to endothelin-1, via a mechanism that involves changes
in the modulatory role of endothelial release of NO and
prostanoids and in the role of endothelin ETA and ETB
receptors. The aim of the present study was to analyse
diabetes-induced changes in the reactivity of the rabbit renal
artery to endothelin-1, including the study of the contribution of
specific receptors and COX-1 and COX-2 derivatives on this
response.
2. Materials and methods
Forty-eight male New Zealand white rabbits were used in the
present study. Animals were randomly divided into two
experimental groups: twenty five in the control group and
twenty three destined for induction of experimental diabetes.
Housing conditions and experimental procedures were in
accordance with the European Union regulations on the use
of animals for scientific purposes (86/609/EEC, Article 5,Appendix II) and as promulgated by Spanish legislation on
March 14, 1988 (RD 223/1988).
2.1. Induction of diabetes and control animals
For induction of experimental diabetes, rabbits weighing
2.0–3.2 kg were sedated with intramuscular injection of
ketamine (40 mg; Ketolar®). Diabetes was induced by injecting
alloxan (100 mg kg−1) into the lateral ear vein. To prevent
hypoglycaemia, 10 ml of glucose 5% was injected intravenous-
ly after the alloxan, and drinking water was supplemented with
10% glucose for the first 24 h after the alloxan injection.
Thereafter, the animals were maintained on tap water and
regular food ad libitum for six weeks. A second group of rabbits
(2.1–3.0 kg) was maintained under the same conditions for the
same time period to serve as age-matched controls (henceforth
“control rabbits”). Diabetic rabbits did not receive insulin
through the six weeks and showed a marked increase in serum
glucose and a failure to increase their body weight when
compared with control rabbits. Table 1 shows the mean values
of body weight and glycaemia before and six weeks after
diabetes induction for the rabbits in the diabetic group and for
the rabbits in the control group.
2.2. Isometric tension recording
Six weeks after diabetes induction, the diabetic and the age-
matched control rabbits were anaesthetised with sodium
thiopental (sodium pentothal, 2%, i.v.) and killed by injection
of potassium chloride (10 mEq, 0.5 ml/kg, i.v.). The renal
arteries were dissected free and cut into cylindrical segments
measuring 4 mm in length. Each segment was prepared for
isometric tension recording in an organ bath. Two stainless steel
L-shaped pins (diameter, 207 μm) were introduced through the
arterial lumen. One pin was fixed to the organ bath wall and the
other pin was connected to a strain gauge for isometric tension
recording (isometric tension transducer models Panlab UF-1
and Letica TRI 201). The organ bath contained 5 ml of Ringer–
Locke solution that was continuously bubbled with 95% O2 and
5% CO2 to provide a pH of 7.3–7.4. Temperature was kept at
37 °C. A resting tension of 2 g was applied to the arterial
segments, and they were allowed to equilibrate for a period of
60–90 min before the experiments were started. Tension was
readjusted when necessary and the bath fluid was changed every
Fig. 1. Concentration–response contractile curves for endothelin-1 in renal
arteries isolated from control and diabetic rabbits: control, incubated with L-
NOARG (10−4 M) and incubated with BQ-123 (10−6 M). Values represent
means±S.E.M.
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arterial segments was checked by depolarisation with 50 mM
KCl. There were not significant differences in the response to
KCl between arteries from control and diabetic rabbits.
2.3. Concentration–response curves of endothelin-1
The experiments were carried out with renal arteries from
both control and diabetic rabbits. Concentration–response
curves for endothelin-1 (10−12–3×10−8 M) were obtained by
its cumulative addition to the organ bath. To assess the
influence of the endothelium on the effect of endothelin-1,
concentration–response curves were obtained with arteries
from which the endothelium had been removed by rubbing
the intimal surface with a scored stainless steel rod (rubbed
arteries). The absence of endothelium was checked either by
silver staining or by testing the absence of relaxant response
to acetylcholine. To assess the participation of NO in the
response of renal artery to endothelin-1, concentration–
response curves for this peptide were obtained after
incubation (20 min) of the renal arteries with the inhibitor
of NO synthase (NOS) NG-nitro-L-arginine (L-NOARG, 10−4
M). To examine the possibility that some arachidonic acid
derivative could modulate the arterial response to endothelin-
1, we obtained concentration–response curves for endothelin-
1 after incubation (20 min) of the arterial segments with either
indomethacin (10−5 M), an inhibitor of cyclooxygenase 1 and
2, or nimesulide (10− 6 M), a selective inhibitor of
cyclooxygenase 2. To verify the endothelial origin of the
arachidonic acid derivatives, concentration–response curves
for endothelin-1 after incubation with indomethacin (10−5 M)
were obtained in rubbed arteries. To check the participation of
specific endothelin ETA receptors, concentration–response
curves for endothelin-1 were obtained in the presence of
selective endothelin ETA receptor antagonist cyclo-(D-Asp-
Pro-D-Val-Leu-D-Trp) (BQ-123, 10− 6 M). To assess the
participation of specific endothelin ETB receptors, concentra-
tion–response curves for endothelin-1 were obtained, in
unrubbed and rubbed arteries, in the presence of selective
endothelin ETB receptor antagonist 2,6-Dimethylpiperidinecar-
bonyl-γ-Methyl-Leu-Nin-(Methoxycarbonyl)-D-Trp-D-Nle
(BQ-788, 10−6 M). Finally, to study the dependence of
arachidonic acid derivatives on the endothelin ETA and ETB
receptors concentration–response curves for endothelin-1 were
obtained in arteries with endothelium in the presence of
indomethacin (10−5 M) plus BQ-123 (10−6 M) and in rubbed
arteries incubated with indomethacin (10−5 M) plus BQ-788
(10−6 M).
2.4. Drugs and solutions
Alloxan, endothelin-1, indomethacin, nimesulide, BQ-123
and BQ-788 were obtained from Sigma and L-NOARG from
Peptide Institute Inc. Alloxan was dissolved in saline solution.
Endothelin-1 was dissolved in 0.1% aqueous acetic acid and
diluted in a mixture of phosphate-buffered saline solution (NaCl
150 mM+NaH2PO4 10 mM) and 0.05% bovine serum albumin.BQ-123, BQ-788 and L-NOARG were dissolved in twice-
distilled water; the L-NOARG solution required sonication to
dissolve completely. Indomethacin and nimesulide were
dissolved in ethanol and diluted in saline solution. The
composition of the Ringer–Locke solution was (mM): NaCl,
120; KCl, 5.4; CaCl2, 2.2; MgCl2, 1.0; NaHCO3, 25; and
glucose, 5.6. To prepare the KCl-depolarising solution, NaCl
was replaced by an equimolar amount of KCl in the normal
Ringer–Locke solution.
2.5. Statistical analysis
Comparisons of body weight and glycaemia between control
and diabetic rabbits were made by using unpaired Student's t-
test. Endothelin-1 induced contractions are expressed as a
percentage of the previous depolarisation induced by 50 mM
KCl. For each concentration–response curve the maximum
effect (Emax) and the concentration of endothelin-1 which
produced half of Emax (EC50) were calculated. Maximum effects
are expressed as mean±S.E.M. and EC50 as the geometric mean
with its confidence limits (95%) for repeated experiments.
Statistical comparisons of Emax and − log EC50 (pD2) values of
the concentration–response curves for endothelin-1 obtained
with the different treatments in the arteries were achieved by
using unpaired Student's t-test. A probability value of less than
5% was considered significant.
3. Results
ET-1 (10−12–3×10−8 M) induced a concentration-depen-
dent contraction of the renal artery from either control or
diabetic rabbits (Fig. 1). The pD2 value of the concentration–
response curve was significantly lower in arteries from diabetic
rabbits than in arteries from control rabbits, without significant
differences between Emax values (Table 2). In arteries from
control rabbits, mechanical removal of the endothelium
significantly increased both the Emax and the pD2 values of
the concentration–response curves for endothelin-1 (Fig. 2,
Table 2
Maximum effect (Emax) and pD2 values for concentration–response curves for ET-1 in rabbit renal artery
Control rabbit Diabetic rabbit
Emax pD2 n Emax pD2 n
Control 99±5 8.98±0.09 22 93±5 8.72±0.07a 23
Rubbed 121±6b 9.34±0.09b 16 103±4a 9.06±0.09a,b 14
L-NOARG 10−4 M 108±6 9.53±0.12b 13 112±4b 8.99±0.05a,b 13
Indomethacin 10−5 M 95±4 8.63±0.12b 20 135±9a,b 9.06±0.13a,b 13
Rubbed indomethacin 10−5 M 130±6b,d 8.92±0.10c,d 17 110±6a,d 8.48±0.06a,b,c,d 11
Nimesulide 10−6 M 129±12b,d 9.08±0.06 7 140±5b 8.87±0.05a 10
BQ-123 10−6 M 72±10b 8.19±0.05b 11 125±5a,b 8.33±0.06b 17
BQ-123 10−6 M+indomethacin 10−5 M 115±7d,e 8.34±0.09b 8 109±6d,e 8.39±0.10b,d 8
BQ-788 10−6 M 129±7b 8.92±0.10 15 91±4a 8.78±0.03 10
Rubbed BQ-788 10−6 M 115±5b 9.18±0.09 8 108±5f 9.30±0.06b,c,f 10
Rubbed BQ-788 10−6 M+indomethacin 10−5 M 165±13b,c,d,f,g,h 9.31±0.09d,f,h 9 126±6a,b,f,g,h 8.99±0.11a,f,g,h 9
Emax values are expressed as a percentage of a previous depolarisation with KCl 50 mmol/l. Emax and pD2 values are means±S.E.M.; n: number of arterial segments.
aSignificantly different from corresponding value in control rabbits, P<0.05; b significantly different from corresponding control value, P<0.05; c significantly
different from corresponding rubbed value, P<0.05; d significantly different from corresponding indomethacin value, P<0.05; e significantly different from
corresponding BQ-123 value, P<0.05; f significantly different from corresponding BQ-788 value, P<0.05; g significantly different from corresponding rubbed BQ-
788 value, P<0.05; h significantly different from corresponding rubbed indomethacin value, P<0.05.
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endothelium significantly increased the pD2 value, without
significant changes in Emax value induced by endothelin-1
(Fig. 3, Table 2). The concentration–response curve for
endothelin-1 obtained in rubbed arteries from diabetic rabbits
showed significantly lower Emax and pD2 values with respect
to the values obtained in rubbed arteries from control rabbits
(Table 2).
Incubation with L-NOARG (10−4 M) significantly enhanced
the pD2 value of the concentration–response curve for
endothelin-1 in arterial segments from control rabbits, without
modifying the Emax value, and enhanced both Emax and pD2
values in arteries from diabetic rabbits (Fig. 1, Table 2). TheFig. 2. Concentration–response contractile curves for endothelin-1 in renal
arteries isolated from control rabbits: control, without endothelium (rubbed),
incubated with indomethacin (10−5 M), rubbed incubated with indometh-
acin (10−5 M), and incubated with nimesulide (10−6 M). Values represent
means±S.E.M.concentration–response curve for endothelin-1 obtained in L-
NOARG pretreated arteries from diabetic rabbits showed a
significantly lower pD2 value with respect to its corresponding
value in arteries from control rabbits, without significant
differences in the Emax values (Table 2).
The incubation of renal arteries from control (Fig. 2) or
diabetic (Fig. 3) rabbits with indomethacin (10−5 M) signifi-
cantly diminished the pD2 value (displaced to the right) of the
concentration–response curve to endothelin-1 in control rabbits
(Fig. 2, Table 2) but increased both Emax and pD2 values in
diabetic rabbits (Fig. 3, Table 2). The Emax and pD2 values of the
concentration–response curve for endothelin-1 obtained in
indomethacin-treated arteries from diabetic rabbits wereFig. 3. Concentration–response contractile curves for endothelin-1 in renal
arteries isolated from diabetic rabbits: control, without endothelium (rubbed),
incubated with indomethacin (10−5 M), rubbed incubated with indometh-
acin (10−5 M), and incubated with nimesulide (10−6 M). Values represent
means±S.E.M.
Fig. 5. Concentration–response contractile curves for endothelin-1 in renal
arteries isolated from diabetic rabbits: control, without endothelium (rubbed),
rubbed incubated indomethacin (10−5 M), rubbed incubated with BQ-788
10−6 M), and rubbed incubated with BQ-788 (10−6 M) plus indomethacin
(10−5 M). Values represent means±S.E.M.
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arteries from control rabbits (Table 2).
The incubation of rubbed renal arteries either from control
(Fig. 2) or diabetic (Fig. 3) rabbits with indomethacin (10−5 M)
significantly diminished the pD2 value of the concentration–
response curve for endothelin-1 with respect to the
corresponding value obtained in rubbed arteries in the absence
of indomethacin (Table 2). The Emax and pD2 values of the
concentration–response curve for endothelin-1 obtained in
indomethacin-treated rubbed arteries from diabetic rabbits
were significantly lower than those obtained in indomethacin-
treated rubbed arteries from control rabbits (Table 2).
The incubation of renal arteries either from control (Fig. 2) or
diabetic (Fig. 3) rabbits with nimesulide (10−6 M) significantly
increased the Emax of the concentration–response curve for
endothelin-1, without modifying the pD2 value (Table 2). The
pD2 value of the concentration–response curve for endothelin-1
obtained in nimesulide-treated arteries from diabetic rabbits was
significantly lower than that obtained in nimesulide-treated
arteries from control rabbits (Table 2).
The incubation with BQ-123 (10− 6 M) significantly
inhibited the contractile response to endothelin-1 of renal
arteries from control rabbits (Fig. 1, Table 2) but enhanced it in
arteries from diabetic rabbits (Fig. 1, Table 2). The incubation of
BQ-123 (10−6 M)-pretreated renal arteries either from control
or diabetic rabbits with indomethacin (10−5 M) significantly
increased the Emax value of the concentration–response curve
for endothelin-1 in control rabbits (Table 2) but inhibited the
Emax value in diabetic rabbits (Table 2) with respect to the
corresponding value obtained in BQ-123 (10−6 M)-pretreated
arteries in the absence of indomethacin.
The incubation of renal arteries from control rabbits with
BQ-788 (10−6 M) significantly increased the Emax value of theFig. 4. Concentration–response contractile curves for endothelin-1 in renal
arteries isolated from control rabbits: control, without endothelium (rubbed),concentration–response curve for endothelin-1, without mod-
ifying the pD2 value (Fig. 4, Table 2). In arteries from diabetic
rabbits, incubation with BQ-788 (10−6 M) did not significantly
modify the contractile response to endothelin-1 (Fig. 5, Table
2). The Emax of the concentration–response curve for
endothelin-1 obtained in BQ-788-treated arteries from diabetic
rabbits was significantly lower than that obtained in BQ-788-
treated arteries from control rabbits (Table 2).
The incubation of rubbed renal arteries either from control
(Fig. 4) or diabetic (Fig. 5) rabbits with BQ-788 (10−6 M) did
not modify (control rabbits) or significantly increased the pD2
value (diabetic rabbits) of the concentration–response curve for
endothelin-1 with respect to the corresponding value obtained in
rubbed arteries in the absence of BQ-788 (Table 2).
The incubation with indomethacin (10−5 M) of rubbed renal
arteries from either control (Fig. 4) or diabetic (Fig. 5) rabbits
pretreated with BQ-788 (10−6 M) significantly enhanced the
contractile response to endothelin-1 with respect to the
corresponding curve obtained in rubbed arteries incubated
only with BQ-788 (Table 2). The Emax and the pD2 values of the
concentration–response curve for endothelin-1 obtained in BQ-
788 plus indomethacin treated rubbed arteries from diabetic
rabbits were significantly lower than those obtained in BQ-788
plus indomethacin treated rubbed arteries from control rabbits
(Table 2).
4. Discussion
Endothelin-1 induced a concentration-dependent contrac-
tion of the rabbit renal artery which was slight but
significantly less potent in arterial segments from diabetic
rabbits, suggesting that diabetes decreases the sensitivity of
the isolated rabbit renal artery to endothelin-1. Several studies
have shown reduced responsiveness to endothelin-1 in the
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Chakravarthy et al., 1994). In patients with diabetes type II
the vasoconstrictor responses to exogenous endothelin-1 are
impaired in the forearm blood flow (Nugent et al., 1996;
Cardillo et al., 2002). In contrast, diabetes does not modify
the contractile response of rat basilar artery to endothelin-1
(Mayhan, 1998) and increases sensitivity of human cutaneous
resistance arteries to endothelin-1 (McIntyre et al., 2001).
Endothelium denudation of arterial rings enhanced the
contractile response of renal artery to endothelin-1, both in
terms of Emax and pD2 in control rabbits, and only in terms of
pD2 (displaced to the left the concentration–response curve for
endothelin-1) in diabetic rabbits, thus indicating that the
endothelium partially counteracts the endothelin-1-mediated
vasoconstriction. The endothelin-1 induced contraction of
endothelium-denuded diabetic arteries was significantly lower
than that obtained in endothelium-denuded arteries from control
rabbits. Therefore, the decreased sensitivity of diabetic renal
arteries to endothelin-1 cannot be attributed to a reduced release
of vasodilator endothelial modulators.
We studied the possibility that the modulatory action of the
endothelium could be achieved, at least partially, through the
release of NO. Incubation of renal arteries from control
rabbits with the inhibitor of the constitutive NOS, L-NOARG,
significantly enhanced the sensitivity of arterial segments to
endothelin-1, without modifying the maximal contraction,
thus indicating the participation of NO in the modulatory
action of the endothelium on this response. This seems
consistent with in vivo studies which have demonstrated that
endothelin-1 stimulates the release of NO in the human
forearm circulation (Cardillo et al., 2000). In arteries from
diabetic rabbits, L-NOARG significantly enhanced the
contraction induced by endothelin-1, both in terms of Emax
and pD2. This result suggests that diabetes enhances the
modulatory action of endothelial NO on the response of the
renal artery to endothelin-1. Results previously obtained in
our laboratory show that experimental diabetes enhances the
modulatory activity of endothelial constitutive NO on the
response of either the rabbit renal artery to acetylcholine
(Alabadí et al., 2001) or the rabbit carotid artery to 5-
hydroxytryptamine (Miranda et al., 2000b). In addition, we
have also reported that diabetes does not modify the
sensitivity of vascular smooth muscle to NO in the rabbit
renal artery (Alabadí et al., 2001). Therefore, our results
suggest that diabetes enhances the production of NO from the
endothelial cells of the rabbit renal artery.
In the present work, we examined the participation of
arachidonic acid metabolites derived via COX in the modula-
tion of the response of the renal artery to endothelin-1. In
arteries from control rabbits, indomethacin, an inhibitor of both
COX-1 and COX-2, significantly decreased the sensitivity of
the renal artery to endothelin-1, but nimesulide, a selective
inhibitor of COX-2, significantly enhanced the contractions to
endothelin-1. Our results suggest that the response of the renal
artery to endothelin-1 is modulated by the release of a
vasoconstrictor prostanoid via COX-1, and a vasodilator
prostanoid via COX-2, predominating the influence of vaso-constrictor prostanoid on that of vasodilator one. These results
are in agreement with those obtained in rats suggesting that
cyclooxygenase metabolites from arachidonic acid contribute to
endothelin-1 afferent arteriolar vasoconstrictor response (Imig
et al., 2000). On the other hand, our results indicate that COX-2
is expressed in the renal artery of control rabbits. COX-2 is
expressed in vasculature of normal adult human kidney
(Therland et al., 2004). Celecoxib, a COX-2 selective inhibitor,
diminishes medullar prostacyclin and thromboxane A2 concen-
tration in the kidney of the rabbit (Miyataka et al., 2002)
lowering the ratio prostacyclin / thromboxane A2 (Lomnicka et
al., 2003). In addition, celecoxib blocks prostacyclin production
of human umbilical vein endothelial cells (Smith et al., 2002).
However, our results are in contrast with the absence of effect of
nimesulide on vasoconstrictor action of arachidonic acid in the
rat kidney suggesting that COX-2 isoform is not expressed
(Quilley and Chen, 2003). Probably, these differences could be
explained because of species variability.
In arteries from diabetic rabbits either indomethacin or
nimesulide significantly enhanced the arterial response to
endothelin-1, suggesting that diabetes alters the balance
between vasoconstrictor (COX-1) and vasodilator (COX-2)
prostanoids in favour of the last ones. This change could
contribute to the decreased sensitivity of the renal artery to
endothelin-1 in diabetes. Several studies have described a
decreased formation of vasoconstrictor prostanoid in rat
mesenteric arterial bed in response to methoxamine (Makino
and Kamata, 1998), rabbit carotid arteries in response to
acetylcholine (Miranda et al., 2000a) or 5-hydroxytryptamine
(Miranda et al., 2000b) and rabbit renal arteries in response to 5-
hydroxytryptamine (Miranda et al., 2002) in diabetes. In
contrast, we have reported an increased production of
vasoconstrictor prostanoids in the carotid artery from diabetic
rabbits in response to endothelin-1 (Lloréns et al., 2004).
Moreover, the renal production of thromboxane A2 and
prostacyclin is increased in diabetic rats (Okumura et al.,
2000). In addition, in rat kidney diabetes induces an increase in
vasoconstrictor prostanoids via COX-2 (Quilley and Chen,
2003). These data support the specificity of the changes in
modulatory mechanisms of the arterial response to endothelin-1
mentioned above, and show that changes in vascular reactivity
induced by diabetes may vary depending on the species,
vascular bed and stimuli studied. A recent study reports the
existence of sex and regional differences in the alterations
induced by diabetes on the reactivity of vascular smooth muscle
(Sanz et al., 2003).
In arteries without endothelium from control and diabetic
rabbits, indomethacin significantly decreased the sensitivity of
the renal artery to endothelin-1 with respect to that obtained in
the absence of the inhibitor, thus suggesting that COX-1
vasoconstrictor prostanoid is released from vascular smooth
muscle cells, as has been described in rat perfused juxtamedul-
lary nephron (Imig et al., 2000).
The vascular actions of endothelin-1 are primarily mediated
by two distinct G-protein-coupled receptor subtypes designated
endothelin ETA and ETB (Hopfner and Gopalakrishnan, 1999).
Both endothelin ETA and endothelin ETB receptors are located
184 V.G. Marrachelli et al. / European Journal of Pharmacology 534 (2006) 178–186in smooth muscle cells and mediate vasoconstriction. Endothe-
lin ETB receptors are also located in the endothelium and
mediate vasodilation through the activation of the release of NO
and prostacyclin. In control rabbits, the antagonist of endothelin
ETA receptors, BQ-123, significantly inhibited the contractile
response of the renal artery to endothelin-1, and the antagonist
of ETB receptors BQ-788 significantly enhanced the contractile
action of endothelin-1. These results are in agreement with
those obtained in rabbits (Evans et al., 2000) and rats (Just et al.,
2004) showing a net vasoconstrictor influence of endothelin
ETA receptors and a net vasodilator influence of endothelin ETB
receptors on renal blood flow.
In diabetic rabbits, BQ-123 significantly enhanced the
contraction of the renal artery to endothelin-1 but BQ-788 did
not modify it. These results suggest that diabetes induces
changes in the role of specific endothelin ETA and ETB
receptors: the activation of endothelin ETA receptors has a net
vasodilator influence, and the activation of endothelin ETB
receptors has no influence or, more probably, there is
equilibrium between vasoconstrictor and vasodilator influence
following their activation. In addition, in the presence of BQ-
788 the contractile response of renal arteries from diabetic
rabbits was lower than that of arteries from control rabbits.
This result suggests that the lower sensitivity to endothelin-1
of renal arteries from diabetic animals could be related to a
lower contractile activity of endothelin ETA receptors. Other
studies have also reported a decrease of vasoconstrictor
activity of endothelin-1 (Makino and Kamata, 1998; McAuley
et al., 2000; Ajayi et al., 2004) in diabetes. However, it has
been reported an enhanced activity of endogenous endothelin-
1 on endothelin ETA receptors in the resistance vessels of
patients with type II diabetes (Cardillo et al., 2002);
nevertheless, the decrease in the contractile action of
exogenous endothelin-1 observed in that study suggests that
the enhanced activity is more related to an increased level of
endogenous endothelin than to an increased sensitivity of the
endothelin ETA receptor.
In the present study we have examined the relationship
between the loss of COX-1 prostanoid vasoconstrictor activity
in diabetes and the observed changes in the role of specific
endothelin ETA and ETB receptors. In arteries from control
rabbits, in the presence of BQ-123 the incubation with
indomethacin enhanced contractile response to endothelin-1,
thus indicating the existence of a net vasodilator influence of
prostanoids activated by endothelin ETB receptors. In contrast,
in arteries from diabetic rabbits, in the presence of BQ-123 the
incubation with indomethacin inhibited contractile response to
endothelin-1, thus indicating the existence in diabetes of a net
vasoconstrictor influence of prostanoids activated by endothelin
ETB receptors. Contractions of guinea-pig gallbladder caused
via ETB receptors are mediated to a large extent by contractile
eicosanoids (Nora et al., 2000).
In rubbed arteries from control rabbits, the incubation with
BQ-788 did not significantly modify the contractile action of
endothelin-1. This result, together with the enhancement of the
contractile response induced by BQ-788 in arteries with
endothelium suggests that the vasodilation after activation ofendothelin ETB receptors is mediated by endothelium, probably
through NO and COX-2 vasodilator prostanoids. Similar results
have been reported showing that the activation of endothelial
endothelin ETB receptors produces vasodilation mediated by
nitric oxide and eicosanoids (Cardillo et al., 2000; D'Orleans-
Juste et al., 2002). In rubbed arteries from diabetic rabbits, the
incubation with BQ-788 increased the contractile potency of
endothelin-1, thus showing the existence in diabetes of a
vasodilatory action mediated by endothelin ETB receptors
(probably through NO and COX-2 vasodilator prostanoids
released from vascular smooth muscle cells). Therefore, our
results suggest that, in diabetes, the activation of endothelin
ETB receptors induces the release of COX-1 vasoconstrictor
prostanoids which counteracts the release of NO and COX-2
vasodilator prostanoids.
Finally, both in control and diabetic rabbits, the incubation
with indomethacin of rubbed arteries pretreated with BQ-788
induced an enhancement of the contractile action of
endothelin-1, thus suggesting that activation of ETA receptors
induces the release from the smooth muscle cells of
prostanoids with a net vasodilator activity. Other studies
have reported the release of vasodilator prostanoids after
activation of endothelin ETA receptors (Wright and Malik,
1995; Nora et al., 2000). The contractile action of endothelin-
1 in rubbed arteries incubated with BQ-788 plus indometh-
acin in diabetic rabbits was lower than the corresponding
action in arteries from control rabbits; because of the fact that
in the absence of indomethacin there were not significant
differences, these results suggest that diabetes diminishes the
vasodilator activity of the prostanoids released from smooth
muscle cells in response to activation of endothelin ETA
receptors. This decreased vasodilator activity would not
explain the loss of vasoconstrictor influence of the activation
of endothelin ETA receptors observed in diabetes, which
could probably be explained by the impairment of COX-1
prostanoid vasoconstrictor release.
In summary, diabetes induces complexes changes in the
regulatory mechanisms that regulate the contractile response of
the rabbit renal artery to endothelin-1: (1) enhancement of
endothelial NO; (2) altered balance between vasoconstrictor
(COX-1) and vasodilator (COX-2) prostanoids in favour of the
last ones; and (3) decreased ratio between vasoconstrictor and
vasodilator prostanoids released after activation of endothelin
ETA receptors predominating on the increased ratio after
activation of endothelin ETB receptors. The sum of these
changes results in a decrease in the sensitivity of the renal
artery to this peptide. The possible vascular implications for
the use of COX-inhibitors and endothelin-related drugs should
be considered in diabetic patients.Acknowledgements
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